Title : Pharmacogenetic study of the impact of ABCB1 single-nucleotide polymorphisms on lenalidomide treatment outcomes in patients with multiple myeloma: results from a phase IV observational study and subsequent phase II clinical trial.

Pub. Date : 2018 Jan

PMID : 29177954






4 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Pharmacogenetic study of the impact of ABCB1 single-nucleotide polymorphisms on lenalidomide treatment outcomes in patients with multiple myeloma: results from a phase IV observational study and subsequent phase II clinical trial. Lenalidomide ATP binding cassette subfamily B member 1 Homo sapiens
2 Lenalidomide (Len) is excreted mainly via the kidneys, and, given the expression of P-gp in the renal tubuli, single-nucleotide polymorphisms (SNPs) in the ABCB1 gene may influence Len plasma concentrations and, subsequently, the outcome of treatment. Lenalidomide ATP binding cassette subfamily B member 1 Homo sapiens
3 Lenalidomide (Len) is excreted mainly via the kidneys, and, given the expression of P-gp in the renal tubuli, single-nucleotide polymorphisms (SNPs) in the ABCB1 gene may influence Len plasma concentrations and, subsequently, the outcome of treatment. Lenalidomide ATP binding cassette subfamily B member 1 Homo sapiens
4 CONCLUSIONS: Our findings show a limited influence of ABCB1 genotype on lenalidomide treatment efficacy and safety. Lenalidomide ATP binding cassette subfamily B member 1 Homo sapiens